The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review
Open accessAbstract
Introduction. Heart failure (HF) is highly prevalent in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) and is strongly associated with mortality in these patients. However, the treatment of HF in this population is largely unclear.Study Design. We conducted a systematic integrative review of the literature to assess the current evidence of HF treatment in CKD patients, searching electronic databases in April 2014. Synthesis used narrative methods.Setting and Population. We focused on adults with a primary diagnosis of CKD and HF.Selection Criteria for Studies. We included studies of any design, quantitative or qualitative.Interventions. HF treatment was defined as any formal means taken to improve the symptoms of HF and/or the heart structure and function abnormalities.Outcomes. Measures of all kinds were considered of interest.Results.Of 1,439 results returned by database searches, 79 articles met inclusion criteria. A further 23 relevant articles were identified by hand searching.Conclusions.Control of fluid overload, the use of beta-blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and optimization of dialysis appear to be the most important methods to treat HF in CKD and ESRD patients. Aldosterone antagonists and digitalis glycosides may additionally be considered; however, their use is associated with significant risks. The role of anemia correction, control of CKD-mineral and bone disorder, and cardiac resynchronization therapy are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 1×
“Several subsequent large RCTs in patients with CKD and ESRD, including the Normal Hematocrit Trial [83], the CREATE (Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta) study [84], the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) study [85], and the TREAT (Trial to Reduce…”
BackgroundMcMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Cited by
Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021) · Circulation · doi:10.1161/circulationaha.120.050686 · Cited by 1,904
Heart failure and kidney dysfunction: epidemiology, mechanisms and management
Schefold, J. C., Filippatos, G., Hasenfuss, G., Anker, S. D., & von Haehling, S. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.113 · Cited by 671
Global epidemiology of heart failure
Khan, M. S., Shahid, I., Bennis, A., Rakisheva, A., Metra, M., & Butler, J. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01046-6 · Cited by 540
Xia, J., Wang, L., Ma, Z., Zhong, L., Wang, Y., Gao, Y., He, L., & Su, X. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw452 · Cited by 285
Xu, K.-Y., Xia, G.-H., Lu, J.-Q., Chen, M.-X., Zhen, X., Wang, S., You, C., Nie, J., Zhou, H.-W., & Yin, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-01387-y · Cited by 261
Metadata
- Authors
- Segall, L., Nistor, I., & Covic, A.
- Venue
- BioMed Research International
- Publisher
- Hindawi Limited
- Published
- 2014
- Volume
- 2014
- Pages
- 1-21
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2170664634
- Cited by
- 158
- References
- 21
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. https://app.cochat.ai/papers/10.1155/2014/937398
- The paper
- Segall, L., Nistor, I., & Covic, A. (2014). Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. BioMed Research International. https://doi.org/10.1155/2014/937398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.